New drugs in phase I and beyond workshop.
Griffiths
R
R
Pfizer Inc, Groton, CT 06340, USA.
Lanni
C
C
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D018102:Receptors, Leukotriene B4; C039351:platelet activating factor receptor